Kathrine F Vandraas1, Kristin V Reinertsen2, Cecilie E Kiserud2, Hanne C Lie2,3. 1. National Advisory Unit for Late Effects After Cancer Treatment, Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway. kathvandraas@gmail.com. 2. National Advisory Unit for Late Effects After Cancer Treatment, Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway. 3. Department of Behavioral Sciences in Medicine, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway.
Abstract
PURPOSE: Fear of cancer recurrence (FCR) may be debilitating, yet knowledge of FCR among the growing population of long-term young adult cancer survivors (YACS) is scarce. We explored risk of FCR and associated factors in a nation-wide, population-based cohort of YACS. METHODS: All 5-year survivors diagnosed at the ages of 19-39 years with breast cancer (BC), malignant melanoma (MM), colorectal cancer (CRC), leukemia (LEU), or non-Hodgkin lymphoma (NHL) between 1985 and 2009 in Norway were identified by the Cancer Registry of Norway and completed the cross-sectional comprehensive NOR-CAYACS health survey. Univariate and multivariate linear regression modeling was performed. RESULTS: In total, 936 survivors were included, with an average of 16 years since diagnoses. BC was the most prevalent cancer form (38.4%), followed by MM (24.7%), NHL (15.6%), CRC (11.8%), and LEU (9.6%). Survivors worried most about getting another cancer (74%), and (20%) reported quite a bit or a lot of FCR. BC and MM survivors had the highest FCR scores. Post-traumatic stress symptoms (PTSS) had the strongest association with FCR (Std B 0.21, p < 0.01), above demographic and clinical variables. CONCLUSIONS: FCR is prevalent even among long-term YACS, including survivors of MM with favorable prognoses. IMPLICATIONS FOR CANCER SURVIVORS: Attention to ongoing risks of PTSS and FCR in this growing survivor population is warranted to optimize future survivorship care.
PURPOSE: Fear of cancer recurrence (FCR) may be debilitating, yet knowledge of FCR among the growing population of long-term young adult cancer survivors (YACS) is scarce. We explored risk of FCR and associated factors in a nation-wide, population-based cohort of YACS. METHODS: All 5-year survivors diagnosed at the ages of 19-39 years with breast cancer (BC), malignant melanoma (MM), colorectal cancer (CRC), leukemia (LEU), or non-Hodgkin lymphoma (NHL) between 1985 and 2009 in Norway were identified by the Cancer Registry of Norway and completed the cross-sectional comprehensive NOR-CAYACS health survey. Univariate and multivariate linear regression modeling was performed. RESULTS: In total, 936 survivors were included, with an average of 16 years since diagnoses. BC was the most prevalent cancer form (38.4%), followed by MM (24.7%), NHL (15.6%), CRC (11.8%), and LEU (9.6%). Survivors worried most about getting another cancer (74%), and (20%) reported quite a bit or a lot of FCR. BC and MM survivors had the highest FCR scores. Post-traumatic stress symptoms (PTSS) had the strongest association with FCR (Std B 0.21, p < 0.01), above demographic and clinical variables. CONCLUSIONS: FCR is prevalent even among long-term YACS, including survivors of MM with favorable prognoses. IMPLICATIONS FOR CANCER SURVIVORS: Attention to ongoing risks of PTSS and FCR in this growing survivor population is warranted to optimize future survivorship care.
Authors: L Kelada; C E Wakefield; L C Heathcote; T Jaaniste; C Signorelli; J E Fardell; M Donoghoe; M C McCarthy; M Gabriel; R J Cohn Journal: Patient Educ Couns Date: 2019-06-26
Authors: Tone Skaali; Sophie D Fosså; Roy Bremnes; Olav Dahl; Carl Fredrik Haaland; Erik Rønneberg Hauge; Olbjørn Klepp; Jan Oldenburg; Erik Wist; Alv A Dahl Journal: Psychooncology Date: 2009-06 Impact factor: 3.894
Authors: Maria C McCarthy; Robyn McNeil; Sarah Drew; David Dunt; Silja Kosola; Lisa Orme; Susan M Sawyer Journal: J Adolesc Young Adult Oncol Date: 2016-05-23 Impact factor: 2.223
Authors: Kathrine F Vandraas; Kristin V Reinertsen; Cecilie E Kiserud; Synne K Bøhn; Hanne C Lie Journal: Support Care Cancer Date: 2022-06-08 Impact factor: 3.359